Background: In the context of established male hypogonadism, testosterone therapy (TTh) has been employed to regain physiologic levels of circulating testosterone and improve sexual function and overall quality of life. Aim: To assess the risk of cardiovascular disease and mortality as time-dependent outcomes in treated vs TTh untreated hypogonadal men. Methods: A meta-analysis using weighted time-related measure of risk (hazard ratios (HRs)) for each of the outcome for all included studies was performed. Studies investigating male adults (& GE;18 years old) diagnosed with hypogonadism and divided into 2 arms (a treatment arm [any TTh] and a control arm [observation or placebo]) and assessing the risk of death and/or cardiovascular events were included. Single arm, non- comparative studies were excluded as well as studies that did not report the HRs for the chosen outcomes. This systemic review was registered on PROSPERO (CRD42022301592) and performed according to MOOSE and PRISMA guidelines. Outcomes: Overall mortality and cardiovascular events of any type. Results: Overall, 10 studies were included in the meta-analysis, involving 179,631 hypogonadal men. Hypogo-nadal men treated with TTh were found to be at lower mortality risk from all causes relative to the control (obser-vation or palcebo) arm (HR: 0.70; 95% Confidence Interval [CI]: 0.54-0.90; P < .01), whilst any unfavorable effect of TTh in hypogonadal men in terms of cardiovascular events compared to untreated/observed hypogona-dal men was found (HR: 0.98; 95% CI 0.73-1.33; P = .89). Clinical implications: TTh in hypogonadal men might play a role in reducing the overall risk of death without increasing cardiovascular events risk. Strengths & Limitation: Main limitations are represented by the high heterogeneity among the studies in terms of included population, definition for hypogonadism, type of TTh, definition of cardio-vascular event used, and the length of follow-up. Conclusion: According to time-related measures of risk only, an increased risk of long-term morbidity and early mortality for untreated hypogonadal men was depicted, further outlining the clinical importance and safety of TTh in true hypogonadal men, with the urgent need of collecting long-term follow-up data. Copyright (c) 2022, International Society of Sexual Medicine.

Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone / G. Fallara, E. Pozzi, F. Belladelli, C. Corsini, L. Boeri, P. Capogrosso, F. Montorsi, A. Salonia. - In: JOURNAL OF SEXUAL MEDICINE. - ISSN 1743-6095. - 19:8(2022 Aug), pp. 1243-1254. [10.1016/j.jsxm.2022.05.145]

Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone

L. Boeri;
2022

Abstract

Background: In the context of established male hypogonadism, testosterone therapy (TTh) has been employed to regain physiologic levels of circulating testosterone and improve sexual function and overall quality of life. Aim: To assess the risk of cardiovascular disease and mortality as time-dependent outcomes in treated vs TTh untreated hypogonadal men. Methods: A meta-analysis using weighted time-related measure of risk (hazard ratios (HRs)) for each of the outcome for all included studies was performed. Studies investigating male adults (& GE;18 years old) diagnosed with hypogonadism and divided into 2 arms (a treatment arm [any TTh] and a control arm [observation or placebo]) and assessing the risk of death and/or cardiovascular events were included. Single arm, non- comparative studies were excluded as well as studies that did not report the HRs for the chosen outcomes. This systemic review was registered on PROSPERO (CRD42022301592) and performed according to MOOSE and PRISMA guidelines. Outcomes: Overall mortality and cardiovascular events of any type. Results: Overall, 10 studies were included in the meta-analysis, involving 179,631 hypogonadal men. Hypogo-nadal men treated with TTh were found to be at lower mortality risk from all causes relative to the control (obser-vation or palcebo) arm (HR: 0.70; 95% Confidence Interval [CI]: 0.54-0.90; P < .01), whilst any unfavorable effect of TTh in hypogonadal men in terms of cardiovascular events compared to untreated/observed hypogona-dal men was found (HR: 0.98; 95% CI 0.73-1.33; P = .89). Clinical implications: TTh in hypogonadal men might play a role in reducing the overall risk of death without increasing cardiovascular events risk. Strengths & Limitation: Main limitations are represented by the high heterogeneity among the studies in terms of included population, definition for hypogonadism, type of TTh, definition of cardio-vascular event used, and the length of follow-up. Conclusion: According to time-related measures of risk only, an increased risk of long-term morbidity and early mortality for untreated hypogonadal men was depicted, further outlining the clinical importance and safety of TTh in true hypogonadal men, with the urgent need of collecting long-term follow-up data. Copyright (c) 2022, International Society of Sexual Medicine.
Cardiovascular; EAU guidelines; Hypogonadism; Mortality; Testosterone
Settore MED/24 - Urologia
ago-2022
23-giu-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
jsm_19_8_1243.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/950948
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact